首页> 外文期刊>Frontiers in Genetics >Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases
【24h】

Effect of Tumor Location on Clinicopathological and Molecular Markers in Colorectal Cancer in Eastern China Patients: An Analysis of 2,356 Cases

机译:肿瘤定位对中国东部患者结直肠癌临床病理和分子标志的影响:2,356例分析

获取原文
       

摘要

Colorectal cancer (CRC) has become a major health concern in China due to its increasing incidence and mortality. This study aimed to clarify the relationship between tumor locations and the clinicopathological molecular marker features in eastern China CRC patients. We continuously collected data on 2,356 CRC patients who underwent surgical resection from January 2017 to April 2019. Right-sided colorectal cancer (RCC), was located from the cecum to the transverse colon and left-side colorectal cancer (LCRC) was located from the splenic flexure to the rectum. The clinicopathological indices (including age, sex, pTNM stage, mucinous production, and distant metastasis) and frequency of molecular markers such as KRAS, NRAS, BRAF, and microsatellite instability (MSI) were statistically analyzed between the RCC and LCRC groups. The associations between clinicopathological characters and molecular markers were also investigated. LCRC and RCC proportions in eastern China CRC patients were 81.75% and 18.25%, respectively. RCC (vs. LCRC) was more frequently observed with higher frequencies of MSI-high (MSI-H) and BRAF mutations in female and younger patients, and was closely associated with metastasis, poor differentiation, and mucinous tumors. Tumor location also showed significant differences in bowel wall infiltration degree and pTNM stage. Mutation rates of KRAS, NRAS, MSI, and BRAF were 40.15%, 3.85%, 6.31%, and 2.30%, respectively. Patients with a KRAS mutation tended to be female, had mucinous, perineural invasive, and polypoid tumor. Those with NRAS mutation tended to develop well-differentiated ulcerative tumors. The BRAF mutation was more relevant with lymph node involvement, deeper infiltration of the bowel wall, mucinous, poorly-differentiated tumor with thrombus, and perineural invasion. Furthermore, MSI-H was more commonly found in younger patients with deeper bowel wall infiltration and a poorly-differentiated polypoid tumor, whereas MSS patients tended to develop lymph node involvement, and a mucinous and perineural invasive tumor. In our study, we found that LCRC and RCC showed different features on the clinicopathological and molecular markers in eastern China CRC patients. Since our data differ from those of Western countries and other regions in China, further studies are required to clarify the regional differences of the clinicopathological and molecular markers in CRC patients.
机译:由于其发病率和死亡率增加,结肠直肠癌(CRC)已成为中国的主要问题。本研究旨在阐明东部CRC患者肿瘤位置与临床病理分子标志特征的关系。我们不断收集关于从2017年1月到2019年1月接受手术切除的2,356名CRC患者的数据。右侧结直肠癌(RCC),位于盲肠到横向结肠和左侧结直肠癌(LCRC)的位置直肠的脾挠曲。在RCC和LCRC组之间统计分析临床病理学指数(包括年龄,性别,PTNM阶段,粘液制剂)和分子标记的频率,例如KRA,NRA,BRAF和微卫星不稳定性(MSI)。还研究了临床病理特征与分子标记之间的关联。中国东部CRC患者的LCRC和RCC比例分别为81.75%和18.25%。 rCC(与LCRC)更频繁地观察到较高频率的MSI-HIGH(MSI-H)和女性和较年轻患者的BRAF突变,并且与转移,分化差和粘液肿瘤密切相关。肿瘤位置还显示出肠壁浸润程度和PTNM阶段的显着差异。 KRAS,NRAS,MSI和BRAF的突变率分别为40.15%,3.85%,6.31%和2.30%。患有KRAS突变的患者往往是女性,具有粘液,危险的侵入性和息肉瘤。具有NRAS突变的人倾向于发育良好分化的溃疡性肿瘤。 BRAF突变与淋巴结受累更相关,肠壁,粘液,差异化肿瘤与血栓的淋巴结渗透,以及麻纹侵袭。此外,MSI-H更常见于患有更深的肠壁浸润和差异差异差异差异差异差异的较差的患者患者中,而MSS患者倾向于开发淋巴结受累,以及粘液和侵袭性侵袭性肿瘤。在我们的研究中,我们发现LCRC和RCC在中国CRC患者的临床病理和分子标记上显示出不同的特征。由于我们的数据与中国的西方国家和其他地区的数据不同,因此需要进一步的研究来阐明CRC患者临床病理学和分子标志物的区域差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号